It has been reported that expression or status of certain molecular markers, such as tumor protein 53 (TP53), epidermal growth factor receptor (EGFR), myelin and lymphocyte protein (MAL), and breast cancer 1/2 (BRCA1/BRCA2) are independent predictors of patient survival in serous ovarian cancer [12–14]. This evidence concerns the gene MAL and ovarian serous adenocarcinoma.